The stock's fall snapped an eight-day winning streak.

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...

Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Gilead’s giving supports community-driven solutions to help end the HIV epidemic for everyone, everywhere, and tackle global ...